Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heungjo Kim

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Clinical Medicine|April 9, 2024
Effect of Multi-Dose Dispensing on Medication Regimen Complexity: A Real-World StudySunmin Lee, Jongsung Hahn, Heungjo Kim, et al.
Scientific Reports|June 11, 2022
Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effectHeungjo Kim, Gyunam Park, Jongsung Hahn, et al.
Journal of Clinical Medicine|June 26, 2025
Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line TherapySungjae Lee, Heungjo Kim, Hongjae Lee, et al.
Computers in Biology and Medicine|January 25, 2025
Population pharmacokinetics of erlotinib in patients with non-small cell lung cancer (NSCLC): A model-based meta-analysisMinJung Kim, Kyongkuk Ryu, Heungjo Kim, et al.
Anesthesiology|December 1, 2025
Effect of Extracorporeal Membrane Oxygenation Flow Rate on Midazolam Clearance: A Population Pharmacokinetic StudyHeungjo Kim, Byung Hak Jin, Seungwon Yang, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Clinical Medicine|April 9, 2024
Effect of Multi-Dose Dispensing on Medication Regimen Complexity: A Real-World StudySunmin Lee, Jongsung Hahn, Heungjo Kim, et al.
Scientific Reports|June 11, 2022
Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effectHeungjo Kim, Gyunam Park, Jongsung Hahn, et al.
Journal of Clinical Medicine|June 26, 2025
Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line TherapySungjae Lee, Heungjo Kim, Hongjae Lee, et al.
Computers in Biology and Medicine|January 25, 2025
Population pharmacokinetics of erlotinib in patients with non-small cell lung cancer (NSCLC): A model-based meta-analysisMinJung Kim, Kyongkuk Ryu, Heungjo Kim, et al.
Anesthesiology|December 1, 2025
Effect of Extracorporeal Membrane Oxygenation Flow Rate on Midazolam Clearance: A Population Pharmacokinetic StudyHeungjo Kim, Byung Hak Jin, Seungwon Yang, et al.
Pageof 1